SCHEMBL2861932

SCHEMBL2861932

O=C(Nc1ccncc1)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HTT P42858 2/20 0.39
NAMPT P43490 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
EGFR P00533 1/20 0.37
PRKACA P17612 1/20 0.37
FRK P42685 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
NEK4 P51957 1/20 0.37
PRKCD Q05655 1/20 0.37
SLK Q9H2G2 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865017 0.89 GRIN2B (0.42) ALDH1A1LMNANAMPTMEN1KMT2A
SCHEMBL2856717 0.89 NPSR1 (0.46) LMNANPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL2870723 0.88 MEN1 (0.39) NPSR1MEN1KMT2ATDP1
SCHEMBL2864826 0.88 F10 (0.40) ALDH1A1LMNANPSR1HTTTDP1
SCHEMBL2862405 0.85 EP300 (0.47) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL2862278 0.84 GRIN2B (0.43) ALDH1A1HTTNAMPTSMN1; SMN2MEN1
SCHEMBL2858289 0.84 RAB9A (0.39) ALDH1A1LMNANPSR1GAASMN1; SMN2
SCHEMBL2863274 0.84 ALDH1A1 (0.41) ALDH1A1NPSR1HTTGAAMEN1
SCHEMBL2861976 0.82 ALDH1A1 (0.40) ALDH1A1LMNANPSR1HTTSMN1; SMN2
SCHEMBL2869316 0.82 NPSR1 (0.35) NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 ALDH1A1 2926/4885LMNA 4583/4885NPSR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.